Study of INCA036978 in Participants With Myeloproliferative Neoplasms
← catalyst calendarNCT07441694 · readout in 1,374 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
218estimated
Sites
54
Countries
Australia, Belgium, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-11 | actual | When the study began enrolling |
| Primary completion | 2030-05-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-24 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myeloproliferative Neoplasms
Interventions
- Drug: INCA036978
- Drug: Standard disease-directed therapy
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Dose Limiting Toxicities (DLT)s in Part 1
measured Up to 28 days
Number of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to approximately 2 years
Number of participants with TEAEs leading to dose modification or discontinuation
measured Up to approximately 2 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed